glp 1 agonist and blindness The Impact of GLP-1 Receptor Agonists on Ocular Disease GLP1 Receptor Agonists—Effects beyond Obesity
Description
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved a new indication for Wegovy (semaglutide) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes.
Discover what the evidence says about berberine, fibre, omega-3, and other natural compounds, plus important safety advice and when to see your GP.
Explore FDA-approved drugs and therapeutic strategies.
Molecular Formula: CHNO
Reduced risk of side effects
The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery
